Aged Blood Transfusion/statistics & numerical data Catheters Indwelling/statistics & numerical data Humans Laser Therapy Male Middle Aged Prospective Studies Prostatic Hyperplasia Randomized Controlled Trials as Topic Transurethral Resection of Prostate Treatment Outcome benign prostatic hyperplasia (BPH) prostate transurethral vaporesection transurethral resection of prostate (TURP)

Embolization Therapeutic Humans Lower Urinary Tract Symptoms/*therapy Male Prostate/*blood supply Prostatic Hyperplasia/physiopathology/*therapy benign prostatic hyperplasia lower urinary tract symptoms meta-analysis prostate artery embolization

Disease Progression Humans Kallikreins/blood Male Metabolic Syndrome Organ Size Prostate/growth & development/pathology/physiopathology Prostate-Specific Antigen/blood Prostatic Hyperplasia/pathology/physiopathology

*Arteries/diagnostic imaging Embolization Therapeutic Humans Kallikreins/blood Male Prostate/*blood supply Prostate-Specific Antigen/blood Prostatic Hyperplasia/diagnostic imaging/*therapy Quality of Life Time Factors Treatment Outcome

Cystectomy/*adverse effects Humans Male Neoplasm Recurrence Local/*diagnosis Prostatic Hyperplasia/diagnosis/*surgery Transurethral Resection of Prostate/*adverse effects Urinary Bladder/*diagnostic imaging Urinary Bladder Neoplasms/diagnosis/*surgery #BladderCancer #blcsm Turbt Turp benign prostatic hyperplasia bladder cancer endoscopic surgery simultaneous surgery

Adult Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use B7-H1 Antigen/antagonists & inhibitors Carcinoma/*drug therapy/immunology/mortality/pathology Clinical Decision-Making Female Humans Immune Checkpoint Inhibitors/adverse effects/*therapeutic use Male Middle Aged Patient Selection Progression-Free Survival Time Factors Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology Urothelium/*drug effects/immunology/pathology Immune-checkpoint inhibitor Meta-analysis Programmed death-ligand 1 Urothelial carcinoma interests/personal relationships which may be considered as potential competing interests: The authors certify that all conflicts of interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the article are listed as follows: Shahrokh Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He has a consulting or advisory role for the following: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Jansen Lilly MSD Olympus Pfizer Pierre Fabre Roche Sanochemia Sanofi Takeda Urogen and Wolff. All remaining authors have declared no conflicts of interest.

Animals Biological Availability Clinical Trials as Topic Flavonoids/pharmacology/*therapeutic use Flavonols/pharmacology/*therapeutic use Humans Inhibitory Concentration 50 Kaempferols/pharmacology/*therapeutic use Male Models Animal Prostatic Neoplasms/*drug therapy Urinary Bladder Neoplasms/*drug therapy bladder cancer fisetin kaempferol myricetin prostate cancer

Endoscopic bladder cancer follow-up surveillance form (available at http://dx.doi.org/10.21037/tau-20-1363). The series “Expectant Management in Genitourinary Malignancies (Prostate Bladder Kidney)” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Quality of life (QoL) bladder cancer non-muscle invasive bladder cancer (NMIBC) surveillance form (available at http://dx.doi.org/10.21037/tau-20-1333). The series “Expectant Management in Genitourinary Malignancies (Prostate Bladder Kidney)” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Androgen Antagonists/*therapeutic use Humans Male Observational Studies as Topic Prostatic Neoplasms/*drug therapy Risk Assessment Urinary Bladder Neoplasms/epidemiology/*prevention & control Androgen deprivation therapy Bladder cancer Pharmacoepidemiology Prostate cancer Systematic review

Coloring Agents Humans Indocyanine Green Lymph Node Excision *Lymphatic Metastasis/diagnostic imaging *Lymphography Male Pelvis *Prostatic Neoplasms/diagnostic imaging/pathology Sentinel Lymph Node Biopsy *Urinary Bladder Neoplasms/diagnostic imaging/pathology Cáncer de Próstata Ganglio centinela Linfadenectomía Lymph node dissection Prostate cáncer Sentinel lymph node Verde de Indocianina

prostate cancer radiation radical prostatectomy radiotherapy secondary bladder cancer

Contrast Media Diagnosis Differential Female Humans Lymphatic Metastasis/*diagnostic imaging/pathology Magnetic Resonance Imaging/*methods Male Prostatic Neoplasms/*pathology Sensitivity and Specificity Urinary Bladder Neoplasms/*pathology Mri bladder cancer lymph node metastasis meta-analysis prostate cancer

Adenocarcinoma/epidemiology/*pathology/surgery Cystectomy/*methods Digital Rectal Examination Humans Incidental Findings Male Neoplasm Recurrence Local/pathology Prognosis Prostate/pathology Prostate-Specific Antigen Prostatectomy/*methods Prostatic Neoplasms/epidemiology/*pathology/surgery Survival Rate Urinary Bladder Neoplasms/*surgery bladder neoplasms cystectomy prostatectomy prostatic neoplasms